Table 1.

Characteristics of HLA‐A*24:02‐positive patients with advanced refractory solid tumors (n = 10) vaccinated with elpamotide

Characteristics	Peptide dose
	0.5 mg (n = 3)	1.0 mg (n = 3)	2.0 mg (n = 4)
Median age (range), years	58 (58–65)	64 (58–70)	57 (30–84)
Male/female	1/2	1/2	3/1
Performance status (0/1)	1/2	0/3	0/4
Non‐small‐cell lung cancer	1	1	2
Gastric cancer	0	1	2
Colorectal cancer	1	1	0
Thyroid cancer	1	0	0